| Previous close | 4.4200 |
| Open | 0.0000 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 0.0000 - 0.0000 |
| 52-week range | |
| Volume | |
| Avg. volume | 174 |
| Market cap | 26.626M |
| Beta (5Y monthly) | -14.14 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0100 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Relief Therapeutics Holding SA / Key word(s): AGMEGM26-May-2023 / 07:00 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.RELIEF THERAPEUTICS Holding SA Announces Notice of Annual General Meeting of ShareholdersGENEVA (May 26, 2023) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFFD, RLFTD) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment option
Relief Therapeutics Holding SA / Key word(s): Regulatory ApprovalRelief Therapeutics Announces Swissmedic Approval and Operation of New Good Manufacturing Practice-Compliant Laboratory 15.05.2023 / 07:00 CET/CESTRelief Therapeutics Announces Swissmedic Approval and Operation of New Good Manufacturing Practice-Compliant Laboratory The state-of-the-art quality control and research and development laboratory in Balerna, Switzerland is run by APR Applied Pharma Research SA, a Relief Therapeutics sub
Relief Therapeutics Holding SA / Key word(s): Miscellaneous12-May-2023 / 23:45 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Relief Therapeutics Has Filed its 2022 Annual Report on Form 20-F with the U.S. Securities and Exchange CommissionGENEVA (May 12, 2023) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFFD and RLFTD) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to del
Relief Therapeutics Holding SA / Key word(s): MiscellaneousRelief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares 03.05.2023 / 07:00 CET/CESTRelief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary SharesGENEVA (May 3, 2023) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief Therapeutics), a biopharmaceutical company committed to delivering innovative treatment options with the potential for transformative outco
Relief Therapeutics Holding SA / Key word(s): Market Launch01-May-2023 / 07:00 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA™ Commercial Launch Progressing Ahead of Schedule Acer reports OLPRUVA™ drug availability anticipated in mid-June 2023; Acer is engaged in discussions with payers representing a substantial majority of covered lives; 70
Relief Therapeutics Holding SA / Key word(s): AGMEGMRelief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders 28.04.2023 / 19:00 CET/CESTRelief Therapeutics Announces Results of Extraordinary General Meeting of ShareholdersShareholders approved all proposals by a large majority; Company to effectuate consolidation of ordinary shares in advance of planned Nasdaq Stock Market dual listing; ADR program will be terminated upon Nasdaq listingGENEVA (April 28, 2023) – RELI
Relief Therapeutics Holding SA / Key word(s): Research Update17-Apr-2023 / 07:00 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100® (Aviptadil Acetate) Relief to file a revised provisional patent application for RLF-100® based on the new stability resultsGENEVA (April 17, 2023) – RELIEF THERAPEUTICS
Relief Therapeutics Holding SA / Key word(s): Annual Results14-Apr-2023 / 07:00 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Relief Therapeutics Announces Full Year 2022 Financial Results and Provides Corporate Update GENEVA, April 14, 2023 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief Therapeutics, or Relief), a biopharmaceutical company committed to delivering innovative treatmen
Relief Therapeutics Holding SA / Key word(s): Personnel05-Apr-2023 / 07:00 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Relief Therapeutics Announces Executive Leadership Team ChangeGENEVA, APRIL 5, 2023 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) ("Relief Therapeutics" or the "Company"), a biopharmaceutical company committed to advancing treatment paradigms to benefit the lives of patie
Relief Therapeutics Holding SA / Key word(s): AGMEGM04-Apr-2023 / 07:00 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders Proposes a reverse stock split of its ordinary shares in preparation for planned listing to the Nasdaq Stock Market GENEVA, APRIL 4, 2023 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) ("Reli
Relief Therapeutics Holding SA / Key word(s): Personnel03-Apr-2023 / 07:00 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Relief Therapeutics Appoints World-Renowned Gene Therapy Pioneer Guangping Gao, Ph.D. as Chair of Scientific Advisory BoardDr. Gao has made foundational contributions in the discovery and characterization of adeno-associated virus (AAV) serotypes which were instrumental in the resurgence of
Relief Therapeutics Holding SA / Key word(s): Study results22-March-2023 / 07:00 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Relief Therapeutics Announces Survey Results Identifying Preferred Urea Cycle Disorder Treatment Attributes Presented by Collaboration Partner at SIMD 2023Acer Therapeutics reports data from a survey of UCD healthcare providers show taste and odor are the most important attributes whe
Relief Therapeutics Holding SA / Key word(s): Study results17-March-2023 / 22:45 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Relief Therapeutics to Present Pre-Clinical Evidence for Improved Amino Acid Utilization with PKU GOLIKE® at the Society for Inherited Metabolic Disorders 44th Annual MeetingThe results of the preclinical study demonstrate improved muscle anabolism and function with a prolonged-releas
Relief Therapeutics Holding SA / Key word(s): Market LaunchRelief Therapeutics Announces Availability of New PKU GOLIKE BARs in Europe 16.03.2023 / 07:00 CET/CEST Relief Therapeutics Announces Availability of New PKU GOLIKE BARs® in Europe The Company also discloses it has transferred most of the funds it held with Credit Suisse and has no funds with recently closed U.S. banksGENEVA, MAR. 16, 2023 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) ("Relief Therapeutics" or the "Com
Relief Therapeutics Holding SA / Key word(s): Market Launch15-March-2023 / 07:00 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement. Relief Therapeutics Provides Update From Collaboration Partner on OLPRUVA™ Acer Therapeutics reports OLPRUVA™ preliminary launch activities progressing; building out commercial and medical affairs teams to support U.S. launch in Q2 2023, with drug availability anticipated by early Ju
Relief Therapeutics Holding SA / Key word(s): Market LaunchRelief Therapeutics Recognizes Rare Disease Day and Announces U.S. Availability of New PKU GOLIKE Bars 28.02.2023 / 07:00 CET/CESTRelief Therapeutics Recognizes Rare Disease Day and Announces U.S. Availability of New PKU GOLIKE® Bars Paolo Galfetti, chief operating officer of Relief Therapeutics and chief executive officer of APR Applied Pharma Research SA, shares his family’s rare story of living with phenylketonuriaGENEVA, FEB. 28, 202
Relief Therapeutics Holding SA / Key word(s): Study14-Feb-2023 / 07:00 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Relief Therapeutics Announces Enrollment of First Three Patients in Proof-of-Concept Clinical Trial of RLF-TD011 for the Treatment of Epidermolysis Bullosa GENEVA, FEB. 14, 2023 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) ("Relief Therapeutics" or the "Company"), a biopharm
Relief Therapeutics Holding SA / Key word(s): Financing08-Feb-2023 / 07:00 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Relief Therapeutics Provides an Update on its Financing Strategy GENEVA, FEB. 8, 2023 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief Therapeutics), today provided an update on its financing strategy and the decision to voluntarily withdraw its Registration Statemen
Relief Therapeutics Holding SA / Key word(s): Study17-Jan-2023 / 06:56 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Relief Therapeutics Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell LymphomGENEVA, JAN. 17, 2023 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief), a biopharmaceutical company identifying, develo
Relief Therapeutics Holding SA / Key word(s): Miscellaneous27-Dec-2022 / 07:15 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission GENEVA, Dec. 27, 2022 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief), announced today that it has filed Amendment No. 2 to its
Relief Therapeutics Holding SA / Key word(s): Regulatory Approval27-Dec-2022 / 07:00 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA™ for Patients with Urea Cycle Disorders New FDA-approved formulation for patients living with urea cycle disorders $42.5 million of non-dilutive debt funding available to Acer that, if drawn, would ext
Relief Therapeutics Holding SA / Key word(s): Legal Matter20-Dec-2022 / 07:00 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement AgreementsGENEVA and RADNOR, PA., DECEMBER 20, 2022 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) ("Relief"), and NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmac
Relief Therapeutics Holding SA / Key word(s): ConferenceRelief Therapeutics to Participate in January Investor Meetings 14.12.2022 / 07:00 CET/CESTRelief Therapeutics to Participate in January Investor Meetings GENEVA, DEC. 14, 2022 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (“Relief”), a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent protected products in selected specialty, rare and ultra-rare disease areas on a
Relief Therapeutics Holding SA / Key word(s): Capital Increase13-Dec-2022 / 07:00 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Relief Therapeutics Announces Issuance of Shares from Authorized Capital Geneva, Dec. 13, 2022 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief), a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent-prot
Relief Therapeutics Holding SA / Key word(s): Personnel08-Dec-2022 / 07:00 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Relief Therapeutics Announces Executive Leadership Team Changes Jack Weinstein, MBA, Appointed as Chief Executive OfficerJeremy Meinen, CPA, Appointed as Chief Financial Officer GENEVA, DEC. 8, 2022 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (“Relief”), a Swiss, commer